Clinical trials at BioNTech for a coronavirus vaccine adapted to the Omicron variant is still going according to plan, the company said.
However, it said it would take some time before the vaccine could be administered.
“We have prepared to be able to deliver the adapted vaccine from the end of March.
- Omicron: CSO urge Saudi Arabia to end Flight suspension on Nigeria
- Oil holds near $80 per barrel as Omicron worries begin to ease
“Logistically, we can implement this,” a BioNTech spokeswoman said.
However, she said all the requirements of the European Medicines Agency (EMA), would also have to be met.
Among other things, the EMA has requested clinical trial data that will be available at the end of April or beginning of May.
The spokeswoman said the timing for approval and delivery had changed accordingly.
“We are still in close contact with the drug authorities in order to be able to deliver the first doses immediately after approval,” she said. (dpa/NAN)
